Scarica l'app Stockscreener
2.17
0.46%
0.010
Precedente Chiudi:
$2.16
Aprire:
$2.15
Volume 24 ore:
6,068
Relative Volume:
0.17
Capitalizzazione di mercato:
$113.62M
Reddito:
$18.85M
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-0.8237
EPS:
-2.6346
Flusso di cassa netto:
$-89.09M
1 W Prestazione:
+2.79%
1M Prestazione:
-7.66%
6M Prestazione:
-16.54%
1 anno Prestazione:
-43.34%
Intervallo 1D:
$2.15
$2.1848
Intervallo di 1 settimana:
$2.1125
$2.2365
Portata 52W:
$1.53
$4.50
Inventiva Adr Stock (IVA) Company Profile
Confronta IVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
2.17 | 113.62M | 18.85M | -119.67M | -89.09M | -2.6346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-12 | Iniziato | UBS | Neutral |
| 2023-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-19 | Aggiornamento | Societe Generale | Sell → Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2022-11-15 | Downgrade | Societe Generale | Buy → Sell |
| 2021-03-08 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Iniziato | ROTH Capital | Buy |
| 2020-08-04 | Iniziato | Guggenheim | Buy |
| 2020-08-04 | Iniziato | Stifel | Buy |
Mostra tutto
Inventiva Adr Borsa (IVA) Ultime notizie
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Inventiva ADR (IVA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - Inventiva
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
Will Election Commission Make Sure That Elections In 2024 Will Be Completely Fair? - Inventiva
Is SBI's Demand For Extra Time To Disclose Details Of Electoral Bonds 1 Attempt To Hide The Doings And Doers Of ‘Great Political Chanda’? - Inventiva
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
National Parties Declare Assets Worth Rs 8,829 Crore In 2021-22: Report - Inventiva
Explosive Showdown: Rahul Yadav-Led 4B Networks Clash with Info Edge in High-Stakes Arbitration Battle - Inventiva
The Indian Chief Ministers Are A Bunch Of Crorepatis While The Average Middle-Class Indian Tax Payer Is Struggling To Survive - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - Inventiva
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Top 10 Best Law Firms In India 2023. - Inventiva
Top 10 Best LegalTech companies in India 2023 - Inventiva
An Interesting Telecom Startup Announced Funding Of INR 30 Crore - Inventiva
TCS, Infosys, Wipro Hire Over 1 Lakh Employees This Fiscal. Know Details - Inventiva
8 US equities have commenced trading on the NSE IFSC in GIFT City; All information about how to start trading through IFSC and should you put money in US stocks? - Inventiva
Innovation And Technology Revolutionizing The Legal Landscape In India 2022 - Inventiva
India Has Its First Most Awaited International Arbitration Centre In Hyderabad In 2021. - Inventiva
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa - Yahoo Finance
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Inventiva Adr Azioni (IVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):